GeoVax Labs shares surge 10.17% intraday after Roth Capital upgrades FY2025 EPS estimates.

GeoVax Labs surged 10.17% intraday following the announcement that Roth Capital upgraded FY2025 EPS estimates for the company. The firm highlighted renewed investor confidence in GeoVax’s pipeline advancements, including positive Phase 2 data for its GEO-CM04S1 vaccine in chronic lymphocytic leukemia patients and regulatory milestones for its GEO-MVA Mpox vaccine. Additionally, favorable European regulatory guidance for GEO-MVA streamlined its development pathway, reinforcing near-term revenue potential. These developments, coupled with D. Boral Capital maintaining a "Buy" recommendation and recent patent allowances for multi-antigen vaccine constructs, collectively drove the sharp intraday rally as market participants priced in accelerated commercial progress and pandemic preparedness positioning.